ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis
NASDAQ:ORGO - Nasdaq - US68621F1021 - Common Stock - Currency: USD
Taking everything into account, ORGO scores 5 out of 10 in our fundamental rating. ORGO was compared to 558 industry peers in the Biotechnology industry. ORGO has only an average score on both its financial health and profitability. ORGO is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ORGO was profitable.
ORGO had a positive operating cash flow in the past year.
Of the past 5 years ORGO 4 years were profitable.
Each year in the past 5 years ORGO had a positive operating cash flow.
1.2 Ratios
The Return On Assets of ORGO (-4.37%) is better than 87.72% of its industry peers.
ORGO has a Return On Equity of -5.55%. This is amongst the best in the industry. ORGO outperforms 90.04% of its industry peers.
With an excellent Return On Invested Capital value of 1.02%, ORGO belongs to the best of the industry, outperforming 91.99% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 14.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROIC | 1.02% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
Looking at the Operating Margin, with a value of 1.13%, ORGO belongs to the top of the industry, outperforming 92.17% of the companies in the same industry.
In the last couple of years the Operating Margin of ORGO has declined.
ORGO has a Gross Margin of 75.85%. This is amongst the best in the industry. ORGO outperforms 83.81% of its industry peers.
In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ORGO has less shares outstanding
ORGO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ORGO has been reduced compared to a year ago.
2.2 Solvency
ORGO has an Altman-Z score of 4.66. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.66, ORGO is doing good in the industry, outperforming 77.22% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that ORGO is not too dependend on debt financing.
ORGO has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: ORGO outperforms 47.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.66 |
ROIC/WACC0.1
WACC10.12%
2.3 Liquidity
A Current Ratio of 4.12 indicates that ORGO has no problem at all paying its short term obligations.
With a Current ratio value of 4.12, ORGO perfoms like the industry average, outperforming 47.51% of the companies in the same industry.
A Quick Ratio of 3.67 indicates that ORGO has no problem at all paying its short term obligations.
ORGO's Quick ratio of 3.67 is in line compared to the rest of the industry. ORGO outperforms 44.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 125.00% over the past year.
ORGO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -37.90% yearly.
ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 5.36%.
Measured over the past years, ORGO shows a quite strong growth in Revenue. The Revenue has been growing by 13.05% on average per year.
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
3.2 Future
ORGO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.29% yearly.
The Revenue is expected to grow by 6.81% on average over the next years.
EPS Next Y-118%
EPS Next 2Y8.17%
EPS Next 3Y24.29%
EPS Next 5YN/A
Revenue Next Year2.62%
Revenue Next 2Y6.21%
Revenue Next 3Y6.81%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 47.78, ORGO can be considered very expensive at the moment.
ORGO's Price/Earnings ratio is rather cheap when compared to the industry. ORGO is cheaper than 92.53% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.41. ORGO is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 21.62, which indicates a rather expensive current valuation of ORGO.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaply inside the industry as 91.99% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 35.19. ORGO is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.78 | ||
| Fwd PE | 21.62 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaply inside the industry as 94.84% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 19.4 |
4.3 Compensation for Growth
The decent profitability rating of ORGO may justify a higher PE ratio.
ORGO's earnings are expected to grow with 24.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.17%
EPS Next 3Y24.29%
5. Dividend
5.1 Amount
No dividends for ORGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.3
-0.1 (-2.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners51.78%
Inst Owner Change0%
Ins Owners31.29%
Ins Owner Change1.49%
Market Cap545.46M
Analysts84.44
Price Target6.38 (48.37%)
Short Float %15.91%
Short Ratio7.48
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)248.79%
Min EPS beat(2)-73%
Max EPS beat(2)570.59%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.47%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)13.3%
Revenue beat(4)3
Avg Revenue beat(4)3.87%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.9%
Revenue beat(12)5
Avg Revenue beat(12)0.29%
Revenue beat(16)7
Avg Revenue beat(16)0.94%
PT rev (1m)0%
PT rev (3m)4.17%
EPS NQ rev (1m)-25%
EPS NQ rev (3m)-400%
EPS NY rev (1m)-180%
EPS NY rev (3m)-157.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.98%
Revenue NY rev (1m)-1.48%
Revenue NY rev (3m)-2.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 47.78 | ||
| Fwd PE | 21.62 | ||
| P/S | 1.19 | ||
| P/FCF | N/A | ||
| P/OCF | 122.99 | ||
| P/B | 1.48 | ||
| P/tB | 1.66 | ||
| EV/EBITDA | 19.4 |
EPS(TTM)0.09
EY2.09%
EPS(NY)0.2
Fwd EY4.63%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)0.03
OCFY0.81%
SpS3.62
BVpS2.9
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROCE | 1.29% | ||
| ROIC | 1.02% | ||
| ROICexc | 1.4% | ||
| ROICexgc | 1.63% | ||
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3Y-38.4%
ROICexcg growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score6
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 65.96% | ||
| Cap/Sales | 2.49% | ||
| Interest Coverage | 1.44 | ||
| Cash Conversion | 19.68% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 4.66 |
F-Score6
WACC10.12%
ROIC/WACC0.1
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-118%
EPS Next 2Y8.17%
EPS Next 3Y24.29%
EPS Next 5YN/A
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
Revenue Next Year2.62%
Revenue Next 2Y6.21%
Revenue Next 3Y6.81%
Revenue Next 5YN/A
EBIT growth 1Y-59.06%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year510.28%
EBIT Next 3Y111.89%
EBIT Next 5YN/A
FCF growth 1Y57.36%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-75.86%
OCF growth 3Y-38.8%
OCF growth 5YN/A